TUFTS MEDICAL CENTER PARENT, INC.
Colorectal cancer is the third leading cause of cancer-related mortality in the USA. This proposal will lay the foundation for the identification of biomarkers which may be used for early detection of colorectal cancer through the analysis of perhaps a single drop of blood. Early diagnosis of colorectal cancer by colonscopy increased the probably of survival. However, this is an invasive screening procedure limited to available endoscopy resoures and patient compliance. Clearly, a robust non-invasive assay is ncessary. In light of recent advances in proteomics, we propose to use mass spectrometry-based methods to identify plasma biomarkers for colorectal cancer. To over come the inherent variability in human studies, the investigator has focused on mouse models of colon cancer. Preliminary data suggest that one is able to identify plasma proteins that act as surrogate markers for cancer in mice with hight tumor burdens. The proposed plan extends that preliminary studies to determine of one can: 1)identify mice with minimal tumor buron, 2)discriminate between mice with tubular and villous adenomas and 3) identify mice with carcinomas.